Statin-induced changes in mitochondrial respiration in blood platelets in rats and human with dyslipidemia

Physiological Research

Volumn 65, Issue 5, 2016, Pages 777-788

  Vevera, J ^a,b   Fisar Z ^a   Nekovarova T ^c,d,e   Vrablik M ^a   Zlatohlavek L ^a   Hroudova J ^a   Singh, N ^a   Raboch, J ^a   Vales K ^c,e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b 7th Field Hospital   (Czech Republic)

^c INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Mitochondria; Platelet; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL; CELL RESPIRATION; DRUG EFFECTS; DYSLIPIDEMIAS; HUMAN; MITOCHONDRION; RAT; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; CELL RESPIRATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MITOCHONDRIA; RATS;

EID: 84997078023     PISSN: 08628408     EISSN: 18029973     Source Type: Journal    
DOI: 10.33549/physiolres.933264     Document Type: Article

References (75)

1. ABDOLI N, HEIDARI R, AZARMI Y, EGHBAL MA: Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes. J Biochem Mol Toxicol 27: 287-294, 2013.
2. ANTóNIO N, SOARES A, FERNANDES R, SOARES F, LOPES A, CARVALHEIRO T, PAIVA A, PROVIDêNCIA LA, GONçALVES L, FONTES RIBEIRO C: Endothelial progenitor cells in diabetic patients with myocardial infarction-can statins improve their function? Eur J Pharmacol 741: 25-36, 2014.
3. BIFULCO M, MALFITANO AM, MARASCO G: Potential therapeutic role of statins in neurological disorders. Expert Rev Neurother 8: 827-837, 2008.
4. BJöRKHEM-BERGMAN L, LINDH JD, BERGMAN P: What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol 72: 164-165, 2011.
5. BöHM M, PAPEZOVA H, HANSIKOVA H, WENCHICH L, ZEMAN J: Activities of respiratory chain complexes in isolated platelets in females with anorexia nervosa. Int J Eat Disord 40: 659-663, 2007.
6. BOLEA I, GELLA A, UNZETA M. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J Neural Transm (Vienna) 120: 893-902, 2013.
7. BOSETTI F, BRIZZI F, BAROGI S, MANCUSO M, SICILIANO G, TENDI EA, MURRI L, RAPOPORT SI, SOLAINI G: Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging 23: 371-376, 2002.
8. BUKKAPATNAM RN, GABLER NB, LEWIS WR: Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol 13: 84-90, 2010.
9. CARDOSO SM, PROENçA MT, SANTOS S, SANTANA I, OLIVEIRA CR: Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 25: 105-110, 2004.
10. CASOLI T, BALIETTI M, GIORGETTI B, SOLAZZI M, SCARPINO O, FATTORETTI P: Platelets in Alzheimer's disease-associated cellular senescence and inflammation. Curr Pharm Des 19: 1727-1738, 2013.
11. CHATTERJEE S, KRISHNAMOORTHY P, RANJAN P, ROY A, CHAKRABORTY A, SABHARWAL MS, RO R, AGARWAL V, SARDAR P, DANIK J, GIRI JS, DEGOMA EM, KUMBHANI DJ: Statins and cognitive function: an updated review. Curr Cardiol Rep 17: 4, 2015.
12. CHEN M, INESTROSA NC, ROSS GS, FERNANDEZ HL: Platelets are the primary source of amyloid β-peptide in human blood. Biochem Biophys Res Commun 213: 96-103, 1995.
13. DA PRADA M, CESURA AM, LAUNAY JM, RICHARDS JG: Platelets as a model for neurones? Experientia 44: 115-126, 1988.
14. DEICHMANN R, LAVIE C, ANDREWS S: Coenzyme Q10 and statin-induced mitochondrial dysfunction. Ochsner J 10: 16-21, 2010.
15. DEMIERRE MF, HIGGINS PD, GRUBER SB, HAWK E, LIPPMAN SM: Statins and cancer prevention. Nat Rev Cancer 5: 930-942, 2005.
16. DESAI CS, MARTIN SS, BLUMENTHAL RS: Non-cardiovascular effects associated with statins. BMJ 349: g3743, 2014.
17. DONOVAN LE, DAMMER EB, DUONG DM, HANFELT JJ, LEVEY AI, SEYFRIED NT, LAH JJ: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease. Alzheimers Res Ther 5: 32, 2013.
18. FELDMAN HH, DOODY RS, KIVIPELTO M, SPARKS DL, WATERS DD, JONES RW, SCHWAM E, SCHINDLER R, HEY-HADAVI J, DEMICCO DA, BREAZNA A; LEADE INVESTIGATORS: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74: 956-964, 2010.
19. FIŠAR Z, HROUDOVá J, HANSíKOVá H, SPáCILOVá J, LELKOVá P, WENCHICH L, JIRáK R, ZVEROVá M, ZEMAN J, MARTáSEK P, RABOCH J: Mitochondrial respiration in the platelets of patients with Alzheimer's disease. Curr Alzheimer Res 13: 930-941, 2016.
20. FRANCO D, FRANCO T, SCHETTINO AM, FILHO JM, VENDRAMIN FS: Protocol for obtaining platelet-rich plasma (PRP), platelet-poor plasma (PPP), and thrombin for autologous use. Aesthetic Plast Surg 36: 1254-1259, 2012.
21. GALTIER F, MURA T, RAYNAUD DE MAUVERGER E, CHEVASSUS H, FARRET A, GAGNOL JP, COSTA F, DUPUY A, PETIT P, CRISTOL JP, MERCIER J, LACAMPAGNE A: Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers. Toxicol Appl Pharmacol 263: 281-286, 2012.
22. GAZZERRO P, PROTO MC, GANGEMI G, MALFITANO AM, CIAGLIA E, PISANTI S, SANTORO A, LAEZZA C, BIFULCO M: Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 64: 102-146, 2012.
23. GNAIGER E, KUZNETSOV AV, SCHNEEBERGER S, SEILER R, BRANDACHER G, STEURER W, MARGREITER R: Mitochondria in the cold. In: Life in the Cold. HELDMAIER G, KLINGENSPOR M (eds), Springer, New York, 2000, pp 431-442.
24. GNAIGER E: Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. 4th ed. Mitochondr Physiol Network 19.12. OROBOROS MiPNet Publications, Innsbruck, 2014, 80 pp. Open Access: www.bioblast.at/index.php/Gnaiger_2014_MitoPathways
25. GOLOMB BA, EVANS MA: Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8: 373-418, 2008.
26. HAUPTMANN S, KEIL U, SCHERPING I, BONERT A, ECKERT A, MüLLER WE: Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Exp Gerontol 41: 668-673, 2006.
27. HOFFMAN KB, KRAUS C, DIMBIL M, GOLOMB BA: A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One 7: e42866, 2012.
28. HROUDOVá J, FIŠAR Z, KITZLEROVá E, ZVEROVá M, RABOCH J: Mitochondrial respiration in blood platelets of depressive patients. Mitochondrion 13: 795-800, 2013.
29. KALRA J, KHAN A: Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease. Eur J Pharmacol 764: 571-581, 2015.
30. KANEEZ FS, SAEED SA: Investigating GABA and its function in platelets as compared to neurons. Platelets 20: 328-333, 2009.
31. KAUFMANN P, TöRöK M, ZAHNO A, WALDHAUSER KM, BRECHT K, KRäHENBüHL S: Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 63: 2415-2425, 2006.
32. KRIGE D, CARROLL MT, COOPER JM, MARSDEN CD, SCHAPIRA AH: Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32: 782-788, 1992.
33. LA GUARDIA PG, ALBERICI LC, RAVAGNANI FG, CATHARINO RR, VERCESI AE: Protection of rat skeletal muscle fibers by either L-carnitine or coenzyme Q10 against statins toxicity mediated by mitochondrial reactive oxygen generation. Front Physiol 4: 103, 2013.
34. LARSEN S, STRIDE N, HEY-MOGENSEN M, HANSEN CN, BANG LE, BUNDGAARD H, NIELSEN LB, HELGE JW, DELA F: Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 61: 44-53, 2013.
35. LENAZ G, D'AURELIO M, MERLO PICH M, GENOVA ML, VENTURA B, BOVINA C, FORMIGGINI G, PARENTI CASTELLI G: Mitochondrial bioenergetics in aging. Biochim Biophys Acta 1459: 397-404, 2000.
36. LI Q, ZHUANG QK, YANG JN, ZHANG YY: Statins excert neuroprotection on cerebral ischemia independent of their lipid-lowering action: the potential molecular mechanisms. Eur Rev Med Pharmacol Sci 18: 1113-1126, 2014.
37. LIM YA, GRIMM A, GIESE M, MENSAH-NYAGAN AG, VILLAFRANCA JE, ITTNER LM, ECKERT A, GöTZ J: Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol. PLoS One 6: e28887, 2011.
38. LLOYD SM, STOTT DJ, DE CRAEN AJ, KEARNEY PM, SATTAR N, PERRY I, PACKARD CJ, BRIGGS A, MARCHBANK L, COMBER H, JUKEMA JW, WESTENDORP RG, TROMPET S, BUCKLEY BM, FORD I: Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS One 8: e72642, 2013.
39. MAES M, FIŠAR Z, MEDINA M, SCAPAGNINI G, NOWAK G, BERK M: New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates?Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20: 127-150, 2012.
40. MALFITANO AM, MARASCO G, PROTO MC, LAEZZA C, GAZZERRO P, BIFULCO M: Statins in neurological disorders: an overview and update. Pharmacol Res 88: 74-83, 2014.
41. MARZILLI M: Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs 10: 3-9, 2010.
42. MCGUINNESS B, CRAIG D, BULLOCK R, PASSMORE P: Statins for the prevention of dementia. Cochrane Database Syst Rev 1: CD003160, 2016.
43. MENDELSON SD: The current status of the platelet 5-HT2A receptor in depression. J Affect Disord 57: 13-24, 2000.
44. MERCADO CP, KILIC F: Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv 10: 231-241, 2010.
45. MERLO PICH M, BOVINA C, FORMIGGINI G, COMETTI GG, GHELLI A, PARENTI CASTELLI G, GENOVA ML, MARCHETTI M, SEMERARO S, LENAZ G: Inhibitor sensitivity of respiratory complex I in human platelets: a possible biomarker of ageing. FEBS Lett 380: 176-178, 1996.
46. MOHAMMADI-BARDBORI A, NAJIBI A, AMIRZADEGAN N, GHARIBI R, DASHTI A, OMIDI M, SAEEDI A, GHAFARIAN-BAHREMAN A, NIKNAHAD H: Coenzyme Q10 remarkably improves the bio-energetic function of rat liver mitochondria treated with statins. Eur J Pharmacol 762: 270-274, 2015.
47. MORRELL CN, AGGREY AA, CHAPMAN LM, MODJESKI KL: Emerging roles for platelets as immune and inflammatory cells. Blood 123: 2759-2767, 2014.
48. NACI H, BRUGTS J, ADES T: Comparative tolerability and harms of individual statins: a study-level network metaanalysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 6: 390-399, 2013.
49. NADANACIVA S, DYKENS JA, BERNAL A, CAPALDI RA, WILL Y: Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 223: 277-287, 2007.
50. OTT BR, DAIELLO LA, DAHABREH IJ, SPRINGATE BA, BIXBY K, MURALI M, TRIKALINOS TA: Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 30: 348-358, 2015.
51. PADALA KP, PADALA PR, MCNEILLY DP, GESKE JA, SULLIVAN DH, POTTER JF: The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 10: 296-302, 2012.
52. PARIHAR A, PARIHAR MS, ZENEBE WJ, GHAFOURIFAR P: Statins lower calcium-induced oxidative stress in isolated mitochondria. Hum Exp Toxicol 31: 355-363, 2012.
53. PESTA D, GNAIGER E: High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol 810: 25-58, 2012.
54. PLáTENíK J, FIŠAR Z, BUCHAL R, JIRáK R, KITZLEROVá E, ZVEROVá M, RABOCH J: GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. Prog Neuropsychopharmacol Biol Psychiatry 50: 83-93, 2014.
55. RAY KK, SESHASAI SR, ERQOU S, SEVER P, JUKEMA JW, FORD I, SATTAR N: Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 170: 1024-1031, 2010.
56. RUSCICA M, MACCHI C, MORLOTTI B, SIRTORI CR, MAGNI P: Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med 25: 401-406, 2014.
57. SATHASIVAM S: Statin induced myotoxicity. Eur J Intern Med 23: 317-324, 2012.
58. SHAD KF, SAEED SA: The metabolism of serotonin in neuronal cells in culture and platelets. Exp Brain Res 183: 411-416, 2007.
59. SHEPARDSON NE, SHANKAR GM, SELKOE DJ: Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 68: 1239-1244, 2011.
60. SHI C, GUO K, YEW DT, YAO Z, FORSTER EL, WANG H, XU J: Effects of ageing and Alzheimer's disease on mitochondrial function of human platelets. Exp Gerontol 43: 589-594, 2008.
61. SIRVENT P, FABRE O, BORDENAVE S, HILLAIRE-BUYS D, RAYNAUD DE MAUVERGER E, LACAMPAGNE A, MERCIER J: Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 259: 263-268, 2012.
62. SJöVALL F, EHINGER JK, MARELSSON SE, MOROTA S, FROSTNER EA, UCHINO H, LUNDGREN J, ARNBJöRNSSON E, HANSSON MJ, FELLMAN V, ELMéR E: Mitochondrial respiration in human viable platelets?methodology and influence of gender, age and storage. Mitochondrion 13: 7-14, 2013.
63. SJöVALL F, MOROTA S, HANSSON MJ, FRIBERG H, GNAIGER E, ELMéR E: Temporal increase of platelet mitochondrial respiration is negatively associated with clinical outcome in patients with sepsis. Crit Care 14: R214, 2010.
64. TAYLOR F, HUFFMAN MD, MACEDO AF, MOORE TH, BURKE M, DAVEY SMITH G, WARD K, EBRAHIM S: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1: CD004816, 2013.
65. VALENTI R, PANTONI L, MARKUS HS: Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review. BMC Med 12: 160, 2014.
66. VALLA J, SCHNEIDER L, NIEDZIELKO T, COON KD, CASELLI R, SABBAGH MN, AHERN GL, BAXTER L, ALEXANDER G, WALKER DG, REIMAN EM: Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 6: 323-330, 2006.
67. VAUGHAN RA, GARCIA-SMITH R, BISOFFI M, CONN CA, TRUJILLO KA: Ubiquinol rescues simvastatinsuppression of mitochondrial content, function and metabolism: Implications for statin-induced rhabdomyolysis. Eur J Pharmacol 711: 1-9, 2013.
68. VEVERA J, FIŠAR Z, KVASNICKA T, ZDENEK H, STáRKOVá L, CEŠKA R, PAPEŽOVá H: Cholesterollowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 133: 197-203, 2005.
69. VEVERA J, VALEŠ K, FIŠAR Z, HROUDOVá J, SINGH N, STUCHLíK A, KACER P, NEKOVáROVá T: The effect of prolonged simvastatin application on serotonin uptake, membrane microviscosity and behavioral changes in the animal model. Physiol Behav 158: 112-120, 2016.
70. XIE Y, DENG S, CHEN Z, YAN S, LANDRY DW: Identification of small-molecule inhibitors of the Aβ-ABAD interaction. Bioorg Med Chem Lett 16: 4657-4660, 2006.
71. XU J, SHI C, LI Q, WU J, FORSTER EL, YEW DT: Mitochondrial dysfunction in platelets and hippocampi of senescence-accelerated mice. J Bioenerg Biomembr 39: 195-202, 2007.
72. YOUDIM MB: Platelet monoamine oxidase B: use and misuse. Experientia 44: 137-141, 1988.
73. YU X, PAN Y, MA H, LI W: Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells. Oncol Res 20: 351-357, 2013.
74. YUBERO-LAHOZ S, ROBLEDO P, FARRé M, DE LATORRE R: Platelet SERT as a peripheral biomarker of serotonergic neurotransmission in the central nervous system. Curr Med Chem 20: 1382-1396, 2013.
75. ZHAO Z, CUI W, ZHANG H, GAO H, LI X, WANG Y, HU H, LI B: Pre-treatment of a single high-dose of atorvastatin provided cardioprotection in different ischaemia/reperfusion models via activating mitochondrial KATP channel. Eur J Pharmacol 751: 89-98, 2015.